Propella Therapeutics, Inc.
https://propellatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Propella Therapeutics, Inc.
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Propella Acquisition To Shore Up Astellas’s Prostate Cancer Presence
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Vizuri Health Sciences LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice